Actively Recruiting
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Led by Shanghai Hengrui Pharmaceutical Co., Ltd. · Updated on 2025-12-19
100
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to evaluate the safety and preliminary efficacy of SHR-7367 in combination with antineoplastic agents in subjects with advanced solid tumors, and to determine the maximum tolerated dose (MTD) and the recommended Phase II dose (RP2D).
CONDITIONS
Official Title
A Study of SHR-7367 With Anti-tumor Agents in Patients With Solid Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide written informed consent
- Aged 18 to 75 years inclusive at the time of consent
- ECOG performance status of 0 or 1
- Life expectancy of at least 12 weeks
- At least one measurable lesion according to RECIST v1.1
- Adequate organ and bone marrow function as defined in the protocol
You will not qualify if you...
- Uncontrollable psychiatric illness or conditions like alcoholism, drug abuse, or criminal detention affecting study participation
- Known hypersensitivity to SHR-7367 or history of severe allergic reactions to similar drugs
- Participation in another clinical study or first dose less than 4 weeks after previous study treatment
- Surgery or chemotherapy within 4 weeks before first study dose
- Active infection with hepatitis B, hepatitis C, or HIV
- Untreated or uncontrolled brain metastases
- Any condition that may increase study risk, interfere with results, or make participation unsuitable as judged by the investigator
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Tianjin Medical University Cancer Institute and Hospital
Tianjin, Tianjin Municipality, China, 300060
Actively Recruiting
Research Team
B
Botao Zhu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here